A second pair of trained eyes,
before the treatment plan is signed.
NgsAdvisory is a physician-led molecular second-opinion practice. We translate next-generation sequencing into a tier-classified, resistance-mapped, signed report, addressed to the oncologist who has to make the call.
The treating physician retains decision authority. We hand them the evidence (tier-classified, sequenced, resistance-mapped) before they sign the plan.
Built around one signature.
The practice is small by design. Every report carries a personal sign-off, the medicine of accountability, not of throughput.
Plate · 014 / Portrait
Prof. Yıldız has spent two decades on the floor of a tertiary oncology service. His thesis is simple: every NGS panel returned to a busy clinic is, in practice, a long PDF that nobody has time to read line by line. The variants that matter are too often the ones nobody flags.
NgsAdvisory is the practice he is opening to staff that gap. A deliberately small reading room, doing one thing: reading panels, cross-checking the literature, and writing the report he himself would have wanted to receive. Every case is read by a physician. Every signature is his own.
Why a second opinion, and why molecular.
at the heart of NGS.
Sequencing has become almost trivial to order. The bottleneck has moved upstream: a 60-page molecular report arrives on a Friday afternoon, mid-clinic, with twenty-two variants of unknown significance and a six-line summary written by a system that has never met the patient.
NgsAdvisory is being built to be that reader. The practice does one thing: re-classify variants, surface what the algorithm misses, sequence the regimens by tier of evidence, and map the resistance pathway one move ahead. The output is a report a physician can sign their own name underneath.
We do not treat. We do not prescribe. We do not replace the treating oncologist or the tumor board. We are the second pair of trained eyes a busy clinic does not have the hours to staff in-house, and that, in molecular oncology, is the difference between a panel and a plan.
Two decades of medical oncology, behind one signature.
NgsAdvisory is a new practice. The numbers below are Prof. Yıldız’s own, the experience he is bringing to the reading room.
What we read against.
Every recommendation in our reports is anchored to a public, peer-reviewed standard. We don’t invent classifications and we don’t borrow from the panel manufacturer. The reading is the work.
Send a panel. Receive a physician-read second opinion.
The practice is open to its first referring oncologists. If you have a sequencing panel that needs a second pair of trained eyes, we read in the order received, target turnaround 72 hours, signed by Prof. Yıldız.